Jul 2026· International Journal of Molecular Medicine· Vol 58, pp. 1-13· 1 citation· 56 references
Medicine
TL;DR
It was demonstrated that the reduction in the levels of lactate levels markedly alleviated renal fibrosis in DKD and indicated that intervention approaches targeting PFKFB3-triggered HIPK2 activation in tubular cells may offer a novel therapeutic strategy for DKD.
Abstract
Aerobic glycolysis is increasingly recognized as a pathogenic driver in diabetic kidney disease (DKD). However, the epigenetic role of its end product, lactate, remains largely undefined. Spatial transcriptomics analysis revealed active glycolysis in tubular epithelial cells. The participation of histone lactylation in DKD was confirmed through inhibition of histone lactylation by glycolysis inhibitors or lactate in vivo. The potential target genes of H4K12 lactylation (H4K12la) were screened by CUT&Tag analyses. The candidate target genes were validated through ChIP-qPCR, RT-qPCR and western blot analyses. The present study found that the expression of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), a pivotal glycolytic regulator, was markedly upregulated in tubular epithelial cells derived from patients with DKD and from the corresponding mouse models. Inhibition of the expression of PFKFB3 mitigated the kidney fibrotic process and alleviated renal function in a DKD mouse model. Conversely, upregulation of PFKFB3 expression aggravated renal fibrogenesis and promoted the deterioration of renal pathology. Moreover, it was demonstrated that the reduction in the levels of lactate levels markedly alleviated renal fibrosis in DKD. With regard to its mechanism of action, lactate was generated via PFKFB3-driven glycolytic reprogramming and selectively enhanced H4K12 lactylation at the homeodomain-interacting protein kinase 2 (HIPK2) promoter, thereby activating its transcription and driving renal fibrotic progression. These findings indicated that PFKFB3 in renal tubules upregulates HIPK2 expression via facilitating H4K12la-dependent gene transcription. Therefore, intervention approaches targeting PFKFB3-triggered HIPK2 activation in tubular cells may offer a novel therapeutic strategy for DKD.
It is demonstrated that the YOD1-KEAP1 axis mediates oxidative stress injury in RTECs and highlight that targeting YOD1 represents a potential treatment approach for DKD.
Qing-Qing Zhao, Ying Zhao, Shi-Jie Fan et al.· Acta Pharmacologica Sinica· 0 citations
Comparison of single‐cell RNA sequencing data of kidney samples from healthy controls and DKD patients reveals a novel S100A1‐MDM2‐KLF15‐ID1 regulatory axis in DKD pathogenesis and suggests targeting S100A1 might be a potential therapy for proximal tubular injury in DKD.
Zhi-Tao Zeng, Jia-Zhen Shang, Shou-Yu Chai et al.· The FASEB Journal· 0 citations
FOXO4 promotes HG-induced HK-2 cell damage and inflammation via regulating TFPI2 in vitro and alleviates renal injury and inflammation in vivo, and TFPI2 knockdown alone alleviates renal injury and inflammation in vivo.
Liqin Mu, Yu Zhao, Yang Li et al.· Kidney Research and Clinical...· 0 citations
It is found that SGK2 suppresses tubular ferroptosis in DKD through NEDD4L-dependent K48-linked ubiquitination and proteasomal degradation of ACSL4, thereby limiting lipid peroxidation and protecting the renal tubules.
Fei Zhang, An-Dong Zhang, Li-Wen Wang et al.· Antioxidants and Redox Signa...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.